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Abstract
The melanoma incidence continues to increase, and the disease remains incurable for many due to 
its metastatic nature and high rate of therapeutic resistance. In particular, melanomas harboring 
BRAFV600E and PTEN mutations often are resistant to current therapies, including BRAF 
inhibitors (BRAFi) and immune checkpoint inhibitors. Abl kinases (Abl, Arg) are activated in 
melanomas and drive progression; however, their mechanism of activation has not been 
established. Here, we elucidate a novel link between BRAFV600E/ERK signaling and Abl kinases. 
We demonstrate that BRAFV600E/ERK play a critical role in binding, phosphorylating, and 
regulating Abl localization and Abl/Arg activation by Src Family Kinases (SFKs). Importantly, 
Abl/Arg activation downstream of BRAFV600E has functional and biological significance, driving 
proliferation, invasion, as well as switch in epithelial-mesenchymal-transition (EMT) transcription 
factor expression, which is known to be critical for melanoma cells to shift between differentiated 
and invasive states. Finally, we describe findings of high translational significance by 
demonstrating that Abl/Arg cooperate with PI3K/Akt/PTEN, a parallel pathway that is associated 
with intrinsic resistance to BRAFi and immunotherapy, as Abl/Arg and Akt inhibitors cooperate to 
prevent viability, cell cycle progression, and in vivo growth of melanomas harboring mutant 
BRAF/PTEN. Thus, these data not only provide mechanistic insight into Abl/Arg regulation 
during melanoma development, but also pave the way for the development of new strategies for 
treating patients with melanomas harboring mutant BRAF/PTEN, which often are refractory to 
current therapies.
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INTRODUCTION
Unlike most cancers, melanoma diagnoses are increasing, particularly in young women 
(<40), and the disease remains incurable for many with metastatic disease (18%-5-year 
survival rate; https://seer.cancer.gov/data/citation.html). Immunotherapies hold promise for 
increasing the cure rate for a proportion of advanced cases; however, for patients with high 
metastatic burden, immunotherapy often is not a first-line option, due to the time needed to 
achieve a response.1 Moreover, only a subset of patients respond.2, 3 Constitutive activation 
of the BRAF serine-threonine kinase (BRAFV600E) is the most common genetic change in 
melanoma.3–5 It is frequently mutated in melanomas derived from intermittant sun-exposure 
(80–90%) and early onset (age ≤39; 86%).4–7 BRAF also is mutated in benign nevi (50–
60%) where it promotes senescence due to high-level, sustained ERK activation.8, 9 
Activation of the PTEN/PI3K/Akt pathway, which modestly down-modulates BRAF/ERK 
signaling, promotes escape from oncogene-induced senescence, and subsequent 
progression.8, 9 BRAFi reduce metastatic burden for some patients with BRAFV600E-
expressing melanomas; however, the majority of responding patients rapidly develop 
resistance, and combined BRAF/MEK inhibitor therapy (BRAFi/MEKi) only delays 
resistance.1, 10 Moreover, BRAFi/MEKi often are less effective for melanomas harboring 
activation of the PI3K/Akt pathway (e.g. PTEN loss), which frequently occurs concurrently 
with BRAF mutations, inducing cytostatic rather than cytotoxic effects, and PTEN mutations 
also are associated with intrinsic resistance to immunotherapy.3, 11–15 Thus, it is imperative 
to identify new drug combinations for treating these patients.
Melanomas originate from neural crest-derived melanocytes, and thus, do not undergo 
classical EMT.16 Instead, melanoma cells are highly plastic, and switch between 
differentiated and invasive states, which contributes to the high rate of metastasis and drug 
resistance.16 This phenotypic shift has been linked to BRAFV600E-induced switch in 
expression of EMT transcription factors from ZEB2 and SNAIL2, which display tumor 
suppressive properties, to ZEB1 and TWIST1, which cooperate with BRAFV600E to induce 
invasion and tumor growth.17 The switch is driven, in part, by ERK-dependent induction and 
phosphorylation of FRA-1, a member of the AP-1 transcription factor family, which binds 
ZEB1, ZEB2, and TWIST1 promoters and regulates their transcription.17 TWIST1 and 
ZEB1 also are regulated by other pathways as SQSTM1/p62 stabilizes TWIST1 protein; 
FOXD3, represses TWIST1 transcription; and ZEB2 induces Microphthalmia-associated 
Transcription Factor (MITF), which represses ZEB1.18–20
The Abelson non-receptor tyrosine kinases, Abl (ABL1) and Arg (ABL2), are most known 
for their involvement in human leukemia; however, accumulating evidence over the past 
decade indicates the kinases also have oncogenic roles in solid tumors.21–23 We and others 
reported that Abl/Arg are activated in melanoma, and drive invasion, proliferation, survival, 
and late stages of metastasis via unique pathways.22, 24–28 However, to date, little is known 
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regarding the mechanism of Abl/Arg activation. In the current study, we show that 
BRAFV600E plays a critical role in activating Abl/Arg, which is required for BRAFV600E 
induction of the EMT transcription factor switch, proliferation and invasion, and Abl/Arg 
also feedback and potentiate BRAF/ERK signaling. Moreover, Abl/Arg synergize with Akt, 
a parallel, cooperating pathway, to drive survival, cell cycle progression, and in vivo growth 
of mutant BRAF/PTEN melanomas. Thus, these data not only uncover a novel link between 
Abl/Arg and BRAFV600E signaling, but also identify a promising therapeutic strategy for 
treating patients with melanomas harboring BRAF/PTEN mutations.
RESULTS
Abl/Arg are overexpressed and activated in melanoma cell lines, and promote invasion and 
proliferation
Previously, we showed that Abl and Arg were highly expressed in six melanoma lines and 
activated in a subset (60%).24 Here, we expanded these studies to 25 human melanoma cell 
lines. Abl/Arg were overexpressed in nearly all lines (compared to melanocytes), and a 
subset (40–60%) also had high basal Abl/Arg activities as determined directly by in vitro 
kinase assay, and indirectly via phosphorylation of endogenous Abl/Arg substrates, Crk and 
CrkL, on Abl/Arg phosphorylation sites (Supplementary Figure S1A, Table S1; denoted 
pCrkL). pCrkL was highly correlative with Abl+Arg but not Src activity, confirming that it is 
a reliable readout of Abl+Arg activity (Supplementary Figure S1B).26, 29, 30 Previously, we 
showed that inhibition of Abl and Arg with 1st (imatinib) or 2nd (nilotinib) generation 
inhibitors, or silencing Abl/Arg with two independent siRNAs, dramatically reduced 
proliferation and invasion (matrigel, 3D) of WM3248 and 435s melanoma lines, which have 
high Abl/Arg activities (Supplementary Figure S1A).24, 25 Here, we identified additional 
lines with high activity (UACC-903 and LOX-IVMI; Supplementary Figure S1A), and 
demonstrate that Abl/Arg inhibition with nilotinib or GNF-2/GNF-5 (highly specific but less 
potent allosteric inhibitors),23, 30 or silencing Abl/Arg with siRNAs reduced proliferation 
and invasion in these lines (Supplementary Figure S1C and S1D).24, 25 Moreover, stable 
expression of an shRNA targeting both Abl and Arg also reduced invasion (Supplementary 
Figure S1E). Thus, Abl and Arg are activated in a subset of melanoma lines and drive 
proliferation and invasion. Cell lines with high Abl/Arg activities (435s, WM3248, 
UACC-903, LOX-IVMI) were used for subsequent studies.
BRAFV600E activates Abl/Arg
Previously, we showed that pCrkL, a highly accepted read-out of Abl+Arg activities 
(Supplementary Figure S1A),26, 29, 31 was elevated in a subset of primary melanomas (40–
60%) using two independent melanoma tissue microarrays.24, 25 Abl/Arg activation was 
high in patients who were diagnosed with melanomas at an early age (≤39; 86%), and in 
melanomas derived from intermittent sun-exposure (61%).25 Interestingly, BRAF mutations 
also occur most frequently in early-onset (74%) melanomas, and in melanomas from the 
intermittent sun-exposure subtype (80–90%).4–7 Thus, we hypothesized that the activities of 
Abl/Arg and BRAFV600E might be linked. To test whether BRAFV600E contributes to 
Abl/Arg activation, BRAF activity was blocked with two independent inhibitors (SB590885, 
PLX-4720-vemurafenib analog), and Abl/Arg activity assessed indirectly (pCrkL; Figure 
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1a), and directly (in vitro kinase assay; Figure 1b), in cell lines harboring BRAFV600E and 
highly active Abl/Arg (WM3248, 435s). Both drugs have little/no activity towards Abl 
(Abl1).32, 33 Abl/Arg kinase activities and pCrkL were reduced following BRAFV600E 
inhibition (Figure 1a,b), even as early as 1–4h after drug treatment (Figure 1b-right). These 
results were not due to off-target effects or direct inhibition of Abl/Arg by the drugs, as 
silencing BRAFV600E also reduced pCrkL and Abl/Arg activities (confirmed in a 3rd cell 
line and with a second siRNA; Figure 1c). Thus, BRAFV600E signaling activates Abl/Arg in 
melanoma cells.
To examine whether BRAFV600E expression is sufficient to activate Abl/Arg, we performed 
gain-of-function experiments using murine melan-a melanocytes, since unlike human 
melanocytes, introduction of BRAFV600E is sufficient to induce their transformation and 
does not induce senescence.17 Consistent with our studies in human melanoma cells, 
introduction of BRAFV600E into melan-a cells induced pCrkL and activated Arg; however, 
Abl activity was reduced, likely due to decreased Abl protein (Figure 1d,e). Importantly, Abl 
loss was due to its translocation to a triton-X-insoluble compartment as increased Abl levels 
were observed in RIPA-solubilized pellets from cells expressing BRAFV600E (Figure 1e, 
bottom). These data indicate that BRAFV600E might alter Abl localization. Unlike Arg 
which is only present in the cytoplasm/plasma membrane, Abl resides in the nucleus, 
cytoplasm and plasma membrane, and can shuttle between nuclear and cytoplasmic 
compartments.34 Activation of nuclear Abl induces apoptosis, which contrasts with its 
transforming role in the cytoplasm.22 To examine whether BRAFV600E alters Abl 
localization, infected melan-a cells were subjected to subcellular fractionation and 
immunofluorescence. Importantly, introduction of BRAFV600E increased expression of Abl 
in the cytoplasm and in long membranous extensions, and reduced its levels in the nucleus 
(Figure 1f; Supplementary Figure S2). These data show for the first time that BRAFV600E 
signaling plays a crucial role in activating Abl and Arg and impacts Abl localization, which 
is critical for its function. Consistent with Abl/Arg and BRAFV600E acting within the same 
pathway, nilotinib and the BRAFi, PLX-4720, did not cooperate to inhibit melanoma 
proliferation (Supplementary Figure S3).
BRAFV600E binds Abl/Arg SH3 domains, and induces Abl/Arg phosphorylation
To unravel the mechanism by which BRAFV600E promotes Abl/Arg activation, we first 
tested whether the proteins are in the same complex. Indeed, Abl and Arg bound to 
BRAFV600E in a heterologous system (Figure 2a), as well as in melanoma cells and ERK 
was in the same complex (Figure 2b). Importantly, GST-pulldown assays demonstrated that 
BRAFV600E but not ERK directly bound Abl and Arg SH3 domains (Figure 2c). Abl/Arg are 
inhibited by SH3 domain-interlinker proline intramolecular interactions, and binding of 
proteins to the SH3 domain relieves autoinhibition.21, 22 Thus, BRAFV600E binding could 
induce Abl/Arg autoactivation. However, catalytically-inactive BRAF (D594A) retained the 
ability to bind Abl, indicating that BRAF binding is not sufficient to activate Abl (Figure 
2d). Rather, BRAFV600E, a serine-threonine kinase, induced Abl threonine phosphorylation 
(Figure 2e), and tyrosine phosphorylation of kinase-inactive Abl or Arg, which lack the 
ability to autophosphorylate (Figure 2f). Thus, BRAFV600E likely promotes Abl/Arg 
phosphorylation by tyrosine kinases that regulate their activities.21, 22 Indeed, Src family 
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tyrosine kinases (SFKs) activate Abl and Arg in melanoma cells (Figure 2g), as we 
demonstrated in other cell types,35, 36 and SFK inhibition prevented BRAFV600E from 
inducing Abl or Arg tyrosine phosphorylation, and inhibited binding of BRAF V600E to Abl 
and Arg (Figure 2h).
BRAFV600E and ERK directly phosphorylate Abl and Arg, in vitro
To identify the mechanism by which BRAFV600E induces Abl/Arg phosphorylation and 
activation, first we tested whether kinases downstream of BRAF (MEK, ERK) mediate the 
effect of BRAFV600E on Abl/Arg activity. Indeed, like the BRAF inhibitor, PLX-4720 
(PLX), MEK (U0126) and ERK (SCH772984; SCH) inhibitors also reduced Abl/Arg 
activities (kinase assays, pCrkL blots; Figure 3a,b), using drug doses that induce similar 
inhibition of pERK. To test whether BRAF, MEK, and/or ERK directly phosphorylate Abl/
Arg, we incubated recombinant forms of Abl or Arg with BRAFV600E or ERK 
immunoprecipitated from BRAFV600E-expressing 293T cells. BRAFV600E and ERK 
efficiently phosphorylated full-length, kinase-inactive Arg (His-Arg-KR), and ERK 
modestly phosphorylated an Abl-SH2-SH3 fragment (Figure 3c). Moreover, recombinant 
forms of BRAF and ERK2 (but not MEK) also phosphorylated His-Arg-KR and kinase-
inactive Abl (K290R; KR) (Figure 3d,e). Thus, we propose the following working model. 
BRAFV600E recruits Abl/Arg to the signaling complex, where ERK (and potentially BRAF) 
subsequently phosphorylate Abl and Arg. This phosphorylation event likely contributes to 
Abl cytoplasmic retention, and facilitates tyrosine phosphorylation of Abl and Arg by SFKs.
Abl/Arg are required for BRAF-mediated switch in EMT transcription factor expression, 
proliferation and invasion, and potentiate BRAFV600E signaling
To understand the functional and biological significance of Abl/Arg activation by BRAF/
ERK, we examined whether Abl/Arg act downstream of BRAFV600E to promote BRAF-
driven processes.17 Expression of BRAFV600E induces ERK-dependent expression and 
phosphorylation of FRA-1, which causes a switch in EMT transcription factor expression 
from ZEB2/SNAIL2 to ZEB1/TWIST1.17 Consistent with these data, ERK1/2 and FRA-1 
were constitutively phosphorylated in melanoma cells that naturally express BRAFV600E 
(WM3248, UACC-903, 435s; Figure 4a). Transfection of siRNAs targeting Abl or Arg, 
expression of an shRNA that silences Abl AND Arg, or treatment with the Abl/Arg 
inhibitor, nilotinib, reduced pERK1/2, pFRA-1/FRA-1, ZEB1, and TWIST1 expression, and 
induced ZEB2 (Figure 4a,b; Supplementary Figure S4A and S4B), indicating that Abl and 
Arg activation is required for the EMT transcription factor switch. Consistent with this data, 
there was a strong trend (Pearson correlation coefficient=0.3, p=0.06; n=40) towards a 
correlation between Arg (ABL2) and TWIST1 mRNA expression in human melanoma 
metastases (Oncomine Riker dataset),37 which became highly significant when the n was 
increased by including all skin cancer samples (Spearman correlation coefficient=0.29, 
p=0.01; n=82). To test whether Abl and/or Arg mediate the effects of BRAFV600E on the 
switch, we examined whether expression of constitutively active forms of Abl or Arg (PP)38 
(using a cumate-inducible system), could rescue reversion of the EMT transcription factor 
switch induced by inhibiting BRAF in melanoma cells harboring BRAFV600E. As expected, 
treatment of vector-transfected cells with the BRAF inhibitor, PLX-4720 (24h), reversed the 
EMT transcription factor (EMT-TF) switch, inhibiting pERK1/2 and pFRA-1/FRA-1, ZEB1 
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and TWIST1 expression, and inducing ZEB2 (Figure 4c,d). Notably, expression of Abl-PP 
rescued the effects of PLX-4720 on TWIST1 and ZEB1, and completely rescued PLX-4720-
mediated inhibition of TWIST1 at short treatment times (2h; Figure 4c,d-right; 
Supplementary Figure S4C). Effects were observed in the absence of cumate due to 
promoter leakiness (Figure 4c), and were enhanced in the presence of cumate (Figure 4d). In 
contrast, neither Abl-PP nor Arg-PP rescued PLX-4720 effects on pERK or pFRA-1/FRA-1. 
Thus, Abl is required for BRAF-driven induction of the EMT-TF switch, and induces 
TWIST1/ZEB1 in an ERK- and FRA-1-independent manner.
Interestingly, Abl-PP and/or Arg-PP expression also increased pFRA-1/FRA-1, pERK1/2, 
TWIST1, and ZEB1 expression in the absence of PLX-4720 (Figure 4c,d-left), indicating 
that Abl/Arg also potentiate BRAFV600E induction of the EMT-TF switch, in addition to Abl 
acting downstream of BRAFV600E. In summary, Abl and Arg activation is required to induce 
the EMT-TF switch; Abl acts downstream of BRAFV600E to regulate TWIST1/ZEB1 
expression in an ERK- and FRA-1-independent manner; and Abl/Arg activation potentiates 
BRAFV600E-mediated induction EMT-TF switch. These data are the first to link Abl/Arg 
activation with the EMT-transcription factor switch, which is a critical step in melanoma 
progression.
Switch in EMT transcription factor expression is linked to increased melanoma proliferation 
and invasion.17, 18, 39 Thus, we tested whether Abl/Arg are required for BRAF-driven 
proliferation and invasion. Significantly, Abl-PP+Arg-PP expression completely rescued 
inhibition of proliferation induced by silencing BRAFV600E (Fig 4e; compare last two bars), 
indicating that Abl/Arg activation downstream of BRAF is required for BRAF-driven 
proliferation. In contrast, Abl-PP+Arg-PP expression only partially rescued BRAF siRNA-
mediated inhibition of matrigel invasion (Figure 4f, compare last two bars), which is likely is 
due, at least in part, to BRAF siRNA-mediated inhibition of exogenous Abl/Arg activity 
(pCrkL) in serum-free conditions (Figure 4f, bottom). Interestingly, as we observed with the 
EMT-TF switch, expression of Abl-PP+Arg-PP also potentiated proliferation and invasion in 
BRAFV600E expressing cells (Figure 4e,f; compare first two bars), which was dependent on 
BRAFV600E expression, as silencing BRAF prevented Abl/Arg-mediated potentiation 
(Figure 4e,f; compare 2nd and 4th bars). Thus, in addition to acting downstream of 
BRAFV600E and driving BRAF-mediated processes, Abl/Arg also feedback and potentiate 
BRAFV600E signaling.
Abl/Arg cooperate with Akt to promote melanoma growth and survival
Since cancers rapidly develop resistance to targeted agents, the future of targeted therapy lies 
in targeting cooperating, compensatory pathways. Melanomas with PTEN mutations 
(activation of Akt), which frequently occurs concurrently with BRAF mutations, often are 
intrinsically resistant to therapy, indicating a need for new therapies for these patients.3, 11–14 
Since Abl/Arg are activated in mutant BRAF/PTEN melanomas (e.g. WM3248, UACC-903; 
Supplementary Figure S1, Table S1), and have little impact on Akt signaling in non-stress 
conditions,40 we hypothesized that Abl/Arg and Akt lie in parallel, cooperating pathways. 
Indeed, inhibitors targeting Abl/Arg (nilotinib; FDA-approved) and Akt (MK-2206; 
allosteric inhibitor) potently synergized to reduce viability of mutant PTEN melanoma cells 
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expressing highly active Abl and Arg (Figure 5a,b). Nilotinib also cooperated with MK-2206 
to block colony formation following drug removal/wash-out, indicating that the effects are 
permanent (Figure 5c,d). Moreover, nilotinib’s effects were Abl/Arg-dependent and not 
mediated by off-target or other on-target effects, as GNF-5 treatment (Figure 5d) or 
expression of an shRNA targeting both Abl and Arg (Figure 5e), also efficiently prevented 
colony formation of cells treated with MK-2206, even when colonies were allowed to form 
for 8d prior to treatment (Figure 5d). Importantly, the mechanism of drug synergy involved 
G1->S cell cycle arrest (Figure 5f and Supplementary Figure S5), and induction of markers 
for apoptosis (PARP cleavage) and G1 arrest/senescence/dormancy ( p27, pRB; Figure 
5g).
Combination Abl/Arg and Akt targeting blocks in vivo growth of mutant PTEN melanomas
To determine whether Abl/Arg and Akt cooperate to promote melanoma growth, in vivo, and 
to assess whether targeting Abl/Arg and Akt pathways could potentially represent a novel 
drug combination for treating mutant BRAF/PTEN melanomas, we treated mice harboring 
mutant BRAF/PTEN melanoma xenografts with vehicle, nilotinib, MK-2206 or the 
combination. Nilotinib was effective on its own in preventing WM3248 xenograft growth, 
comparable to effects observed with MK-2206, but was inefficient at reducing the growth 
rate of UACC-903 xenografts as a monotherapy, consistent with colony-forming assays 
(Figure 6a,b and 5c-right). However, importantly, Abl/Arg and Akt inhibitors dramatically 
cooperated to prevent WM3248 and UACC-903 growth, in vivo (Figure 6a,b). Moreover, 
nilotinib, MK-2206, and the combination did not significantly alter animal body weight 
(Figure 6c) or induce other signs of toxicity (e.g. anemia-pale paws, etc.). Similar to in vitro 
results, the drug combination inhibited RB phosphorylation (an indicator of G1 arrest) in the 
small residual tumors (30–100mm3) from combination-treated animals (Figure 6d). 
Importantly, nilotinib’s effects were Abl/Arg-dependent (not due to off-target or other on-
target effects) as silencing Abl and Arg with an shRNA targeting both proteins, also 
significantly sensitized xenografts to MK-2206 treatment (Figure 6e). Taken together, these 
data indicate that targeting Abl/Arg together with Akt may be an effective treatment strategy 
for mutant BRAF/PTEN melanomas.
DISCUSSION
This study establishes a novel functional link between BRAFV600E and Abl family kinases. 
We identify a new mechanism of Abl/Arg activation, and demonstrate that their activation 
has important functional consequences downstream of BRAFV600E and also feedback and 
potentiate BRAF/ERK signaling (Figure 7). Moreover, we report data of major translational 
significance by showing that Abl/Arg and Akt inhibitors potently cooperate to prevent the 
growth of mutant BRAF/PTEN xenografts.
Abl/Arg proto-oncogenes are tightly regulated, and are kept in an inactive state via 
intramolecular interactions.21, 22 We show that BRAFV600E directly binds Abl/Arg SH3 
domains, which bind conserved PxxP binding motifs.41 BRAF contains 5 PxxP motifs, and 
one is highly similar to those found in other Abl-SH3 binding proteins.41 Interestingly, 
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BRAF binding is insufficient to induce Abl/Arg activation, but rather serves to recruit the 
kinases to the signaling complex, which, interestingly, is dependent on SFK activity.
We provide the first evidence that Abl/Arg drive the EMT transcription factor switch, which 
contributes to melanoma metastasis and drug resistance.16 Abl/Arg activity is required for 
FRA-1 expression/phosphorylation, induction of TWIST1 and ZEB1, and repression of 
ZEB2. Moreover, Abl drives TWIST1/ZEB1 expression downstream of BRAFV600E 
independent of FRA-1/ERK, which indicates that regulation of the switch may not follow a 
simple linear pathway (FRA-1->ZEB1/TWIST1), and likely involves multiple levels of 
regulation. Consistent with these data, TWIST1 and ZEB1 also are regulated via other 
mechanisms, seemingly independent of ERK/FRA-1 signaling.18–20 In addition to mediating 
BRAF-induction of the EMT transcription factor switch, Abl/Arg also are required for 
BRAF-driven proliferation, which might occur via effects on TWIST1/ZEB1, since 
TWIST1/ZEB1 not only promote invasion, but also drive melanoma proliferation and cancer 
stem cell features (Figure 7).17, 18, 39, 42 Interestingly, in addition to acting downstream of 
BRAFV600E, Abl/Arg also potentiate proliferation, invasion, and the EMT-TF switch in the 
presence of BRAFV600E. Importantly, Abl/Arg induce BRAFV600E expression, as Abl-PP 
and Arg-PP increase BRAFV600E protein, whereas silencing Abl/Arg reduces BRAFV600E 
expression (Supplementary Figure S6). Thus, Abl/Arg likely potentiate BRAFV600E 
signaling by increasing BRAFV600E expression. Alternatively, it is also possible that 
Abl/Arg affect the activity of upstream proteins (e.g. Ras or RTKs).43, 44
BRAFi reduce proliferation and metastatic burden, but often are inefficient at preventing 
viability, and their lack of permanent effects results in resistance.10 MEKi extend survival 
for patients with BRAFi resistance, but have on-target toxicity, and recurrent disease is 
aggressive and refractory to treatment (including immunotherapy) due to activation of 
STAT3-dependent invasion.45–47 Moreover, patients whose melanomas harbor PTEN 
mutations often are less responsive to BRAFi/MEKi and immune checkpoint 
inhibitors.3, 11–14 In contrast to BRAFi/MEKi, Abl/Arg inhibitors block STAT3 activation, 
invasion, and metastasis.24, 25 Furthermore, combined inhibition of Abl/Arg and Akt 
pathways, in melanomas harboring mutant BRAF/PTEN, permanently inhibits colony 
formation (even when drugs are introduced after colonies develop), induces apoptosis and 
cell cycle arrest, and dramatically prevents melanoma growth, in vivo. These data are of high 
translational significance as they indicate that dual inhibition of Abl/Arg and Akt may 
represent a novel synthetic lethal strategy, and thus, could pave the way for the development 
of a novel drug combination for patients harboring mutant BRAF/PTEN melanomas 
(intermittent sun-exposure subtype), which often are resistant to therapy. Importantly, Abl 
and Arg are successful drug targets in other cancer types,21 and Abl/Arg inhibitors that also 
block c-Kit activity (imatinib, nilotinib) have been successfully used to treat melanomas 
harboring c-Kit mutations (acral, mucosal, chronic sun-exposure subtypes).48, 49 The 
availability of a plethora of drugs targeting Abl and Arg, which are relatively non-toxic and 
several of which are FDA-approved, is likely to facilitate rapid translation of these findings 
to the clinic.
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MATERIALS AND METHODS
Reagents
Cell Lines—WM lines, 451-LU, 1205-Lu, Mel-1617, UACC-903 were obtained from Dr. 
Herlyn in 2010 (UACC-903-2014), and authenticated in 2011 (Herlyn lab). MDA-MB-435s-
termed 435s, was authenticated (genetically identical to M14) in 2012.24 Melan-a was from 
Welcome Trust (UK; 2015). All other lines were from NCI (NCI-60; 2015). Lines were 
negative for mycoplasma (Lonza MycoAlert; Portsmouth, NH; tested 8/16), and were 
passaged <1 month. WM3248 cells expressing IPTG-inducible shRNA targeting Abl and 
Arg (PLK01-IPTG-3XLacO vector; see Supplemental Materials for plasmid descriptions), 
non-inducible shRNA targeting Abl and Arg (psiStrike-hygro vector), or Abl-PP and/or Arg-
PP (Piggybac cumate vector) were obtained following lentiviral infection (IPTG-shRNA) or 
transfection (pStrike-shRNA; Abl/Arg-PP), and selection with puromycin (2.5μg/ml). For 
shRNA-expressing cells clones were picked, expanded, screened for knockdown by western 
blot, and pooled. Inducible shRNA-expressing cells were treated with IPTG (1mM; 6 days) 
prior to screening. For cells expressing Abl-PP and/or Arg-PP (Piggback cumate inducible, 
transposon vector), polyclonal populations were utilized. FACS indicated >90% of cells 
were GFP-positive.
Drugs—Nilotinib was provided by Novartis (Basel, Switzerland). MK-2206 (Akt inhibitor; 
in vitro studies), GNF-2/GNF-5 (allosteric Abl/Arg inhibitors), SCH772984 (ERK inhibitor) 
and PLX-4720 (BRAF inhibitor) were from Selleck (Houston, TX). Some studies utilized 
PLX-4720 from Plexxicon (Berkeley, CA). MK-2206 (in vivo studies) was from MedChem 
Express (Monmouth Junction, NJ). SU6656 was from Millipore (Billerica, MA). Captisol 
was from Ligand Pharmaceuticals (San Diego, CA). Cumate was obtained from Systems 
Biosciences, and IPTG from Invitrogen (Carlsbad, CA).
Antibodies—Antibodies were obtained from the following companies. Sigma-Aldrich: β-
actin and Arg (5C6; western). Santa Cruz Biotechnology (Santa Cruz, CA): Abl (K12; 
kinase assay; K12-AC for endogenous coIP), c-myc (9E10), BRAF [C19 (IP), F-7 (IP, 
Supplementary Figure S8-western blot), H-145 (all other western blots)], TWIST1 (2C1A), 
ZEB1 (H-102), ZEB2 (H-160), FRA-1 (R-20; Fig. 4B only), and HRP-conjugated secondary 
antibodies. Cell Signaling (Danvers, MA): FRA-1, pCrkL (recognizes Abl/Arg 
phosphorylation sites on substrates Crk (Y221) and CrkL Y207)), CrkL (32H4), pAkt, Akt 
(#9272), p-p38, p38 (#9212), pRB (S807/811), RB (4H1), p27 (D37H1), pFRA-1, phospho-
threonine. BD Biosciences (San Jose, CA): Abl (8E9; western blot) and pan-ERK (16/ERK). 
Promega (Madison, WI): phospho-ERK. Millipore (Billerica, MA): phospho-tyrosine 
(4G10), phospho-serine (4A4), Src (GD11), and Lamin A/C (clone 14). ThermoFisher: α-
tubulin (RB9249-P0). The Arg kinase assay antibody and recombinant proteins (Abl, Arg) 
were previously described.36, 50 Full-length GST-BRAF, His-MEK, GST-ERK2, and 
siRNAs were from ThermoFisher (Waltham, MA). siRNAs: Abl: ss866 (10nM, #1); ss864 
(10nM; #2); 1336 (20nM, #3); Arg-ss872 (10nM, #1), ss363 (10nM, #2), 1478 (20nM, #3); 
BRAF: ss2080 (5nM, #1), ss2081 (10nM, #2). shRNA sequence that targets Abl and Arg 
was GGGAAATTGCTACCTATGG (see Supplementary Materials for plasmid descriptions).
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Cell Transfection
293T cells were transfected with calcium phosphate,51 Lipofectamine 2000 (Invitrogen) was 
used for melanoma lines, and melan-a cells were infected with BRAFV600E retrovirus 
(8h).51 WM3248 cells were infected with commercial IPTG-inducible shRNA lentivirus 
(10μl/96-well; non-targeting shRNA=2.2x107Tu/ml: Abl/Arg-shRNA=3.7x106 Tu/ml) in the 
presence of 8μg/ml polybrene (16h).
Western Blots, Coimmunoprecipitations, GST-Pulldowns, and Kinase Assays
Cells were lysed in kinase lysis buffer (kinase assays, GST-pulldowns),51 RIPA (westerns),51 
or TNEN (coimmunoprecipitations).52 Proteins were immunoprecipitated or GSTs used for 
pulldown, and complexes washed (TNEN for coimmunoprecipitations; RIPA/+NaCl/-NaCl 
for kinase assays).51 For kinase assays, immunoprecipitates were incubated in Abl/Arg51 or 
BRAF53 kinase buffers containing 1μM cold ATP, 5μCi 32P-γ-ATP, 1μg substrate (Abl/
Arg-40′, 25°C, GST-Crk substrate; BRAF/MEK/ERK-30′, 30°C, Abl/Arg substrates). For 
assays using recombinant proteins, 20ng of BRAF/MEK/ERK and 500ng of His-Arg-KR 
were utilized. Kinase assays and westerns were quantitated using a Storm Phosphoimager 
(GE Healthcare; Pittsburgh, PA) and Image J64, respectively.
Matrigel invasion Assays
Assays were performed as described.24, 35 IGF-1 (10nM; 48h invasion) was used as 
chemoattractant for UACC-903 and WM3248 cells, whereas EGF (100ng/ml; 24h invasion) 
was used for LOX-IVMI.
Subcellular Fractionation
Cytoplasmic/nuclear lysates were prepared with NE-PER (ThermoFisher).40
Proliferation and Viability Assays
Viability-CellTiter Glo (Promega). Assays were performed using three drug doses (alone/
combination).40 Proliferation-3H-Thymidine. Tritiated thymidine incorporation was 
measured in labeled cells (drug treatment=24h, label=last 2h; siRNAs=72h transfection, 
label=24h).40 BrdU/FACS. Cells were treated for 72h (media/drugs refreshed after 48h), 
stained with anti-BrdU antibody (BD Biosciences, Chicago, IL), and analyzed by FACS 
(Cell Quest software/Modfit analysis; Verity Software House, Topsham, ME)40. Clonogenic 
Assays. Cells were treated (72h; drugs refreshed after 48h), washed, media replaced without 
drugs, and colonies fixed (4% paraformaldehyde), and stained (0.5% crystal violet). For 
some experiments, 72h treatment was initiated after colonies formed (8d).
Xenograft Assays
WM3248 (3X106) and UACC-903 (1X106), in HEPES-Buffered-Saline, were injected 
subcutaneously in 6-week old female nude mice (Harlan; Indianapolis, IN). Mice whose 
tumors grew in 9–12 days (30–100mm3) were blindly/randomly assigned to groups. 1) 
Vehicle. Nilotinib-vehicle (0.5% hydroxymethylcellulose/0.05% Tween-80-b.i.d., oral 
gavage) plus MK-2206-vehicle (30% captisol-3X/week, oral gavage); 2) Nilotinib (33mg/kg, 
oral gavage, b.i.d.) plus MK-2206-vehicle; 3) MK-2206 (90mg/kg/day for WM3248; 
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120mg/kg/day for UACC-903 and WM3248-shRNA; 3X/week; oral gavage) plus nilotinib-
vehicle; 4) Nilotinib+MK-2206. Tumors were measured 3X/week, and animals euthanized 
when largest tumors were >800mm3. Experiments were performed under IACUC protocol 
#00946M2005, in accordance with University and NIH guidelines. Power Analysis. Ten 
mice/group provided 85% power to detect a 50% and 75% reduction in tumor volume for 
single and combination groups, respectively, compared to mean=600mm3 (SD=225mm3) in 
the vehicle group (ANOVA; 1% alpha; adjusted for multiple pairwise testing).
Immunohistochemistry (IHC) and immunofluorescence (IF)
IHC. Antigen retrieval was performed in low pH Retrieval Solution (Dako, Carpinteria, CA), 
followed by incubation with pRB antibody (1:50; overnight; 4°C), amplification with rabbit 
linker (Dako), and detection with Immpress anti-rabbit-AP and Immpact Vector Red (Vector 
Laboratories; Burlingame, CA). Slides were scanned on an AperioScope (Vista, CA). IF. 
Cells, plated on coverslips, were fixed (4% formaldehyde), permeabilized (0.1% triton-X), 
blocked (3% BSA), and incubated with Abl (mouse 8E9; 1:50; overnight, 4°C)34 and BRAF 
(rabbit H-145; 1:500; 2h, 4°C) antibodies, followed by anti-mouse Alexa-488 and anti-rabbit 
Alexa-555 secondary antibodies (1:100; Cell Signaling; 1h), and mounted in ProlongGold 
antifade (Invitrogen). Images were captured on an Olympus Fluoview™ FV1000 Confocal 
microscope, 60X objective, V1.7 software, using Arg Ion (488nM excitation for Alexa-488), 
HeNe (543nm excitation for Alexa-555), and Diode lasers (405nm DAPI).
Statistics
Analyses were performed with SAS (V9.3), R (V3.3.1), or the Vassar Website. Tukey HSD 
test was used for multiple comparison adjustments for ANOVA, whereas Holm’s method 
was used for paired t-tests (comparisons against normalized controls) and unpaired Welch’s 
t-test (comparisons between groups). All reported values are two-tailed. Variation was 
presented as standard error of the mean (SEM) for each group. Parametric tests were 
performed after checking data normality (Shapiro-Will tests if samples sizes were sufficient) 
and homogeneity of variance (Bartlett’s tests if necessary). Otherwise, nonparametric tests 
were performed. Microarray data were downloaded (Oncomine),37 and Pearson’s or 
Spearman’s correlation coefficient used to quantify correlations. Combination indices were 
calculated with CalcuSyn software (Biosoft; Cambridge, UK).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. BRAFV600E contributes to Abl/Arg activation in melanoma cells
(a,b) Human melanoma cell lines were serum-starved and treated with vehicle (V; DMSO) 
or BRAF inhibitors for 24h (a, b-left) or 1–4h (b-right), and phosphorylation of Abl/Arg 
substrate, CrkL (a) (western blot) or Abl/Arg kinase activities (b) (in vitro kinase assay 
using GST-Crk as substrate) assessed. Mean±SEM, n=3. *p<0.05, **p≤0.01 using one-
sample t-tests and Holm’s adjustment for multiple comparisons.
(c) Kinase assays and western blots were performed on lysates from serum-starved, siRNA-
transfected cells (72h). Scrambled=Scr, BRAF=BR. Mean±SEM, n=3. *p<0.05, **p≤0.01, 
***p<0.001 using one sample t-tests.
(d,e) Western blots (d,e-bottom) or kinase assays (e-top) were performed on RIPA (d) or 
triton-X (e) lysates from melanocytes expressing vector (−) or myc-tagged BRAFV600E 
(48h) in the presence (d) or absence (e) of serum. Triton-insoluble pellets were solubilized 
with RIPA buffer (e, bottom). Mean±SEM, n=4. **p<0.01 using a one-sample t-test.
(f) Subcellular fractionation on retrovirally infected melan-a cells. Mean±SEM, n=3. 
*p<0.05, **p≤0.01; one-sample t-tests. Control blots (lamin, α-tubulin) indicate fraction 
purity. Nuclear ZEB2, which is repressed by BRAF,17 also is reduced in BRAFV600E-
expressing cells.
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Figure 2. BRAFV600E binds and induces Abl/Arg phosphorylation
(a,b,d) Coimmunoprecipitations. myc-tagged-BRAFV600E, Abl, or Arg was 
immunoprecipitated from 293T cells expressing wild-type Abl or Arg (Migr1-Abl-WT, 
pcDNA-Arg-WT) and myc-tagged BRAFV600E (a), or from 293T cells expressing wild-type 
Abl (pSRα-Abl-WT) and catalytically-inactive BRAF (D594A) (d), and immunoprecipitates 
blotted with the indicated antibodies. (b) Endogenous Abl or Arg were immunoprecipitated 
from WM3248 melanoma cell lysate and blotted with the indicated antibodies. IgG isotype-
matched control antibody was used in parallel immunoprecipitations.
(c) GST-pulldown assay using lysate from 293T cells transfected with myc-BRAFV600E 
(exogenous BRAFV600E) or WM3248 cells expressing endogenous BRAFV600E and 
recombinant fragments of Abl or Arg fused to GST (isolated in bacteria). Bands in long 
exposure of ERK blot are GST-fusion proteins.
(e,f) Immunoprecipitation followed by western blotting using 293T cells transfected with 
vector (pBabePuro) or myc-BRAFV600E together with wild-type (WT; Migr1-Abl-WT, 
pcDNA-Arg-WT) or kinase-inactive (KR; pSRα-Abl-KR, and pcDNA-Arg-KR) Abl or Arg.
(g) Melanoma cells were treated with vehicle (V; DMSO) or SFK inhibitor, SU6656 (10μM; 
24h), serum-starved, and western blot or kinase assays performed on the lysates.
(h) Abl or Arg immunoprecipitates from vector- (pBabePuro) or myc-BRAFV600E-
transfected 293T cells, treated with vehicle (DMSO) or SU6656 (10μM; 24h), were blotted 
with the indicated antibodies.
Jain et al. Page 16
Oncogene. Author manuscript; available in PMC 2017 October 03.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 3. BRAFV600E and ERK directly phosphorylate Abl and Arg in vitro
(a) Cells were treated with vehicle (V; DMSO), BRAF inhibitor, PLX-4720 (PLX; 1μM) or 
MEK inhibitor (U0126; 5μM) for 4h, serum-starved, and lysates subjected to in vitro kinase 
assay or western blot.
(b) Cells were treated with BRAF inhibitor (PLX-4720=PLX; 1μM), ERK inhibitor 
(SCH772984=SCH; 0.1μM) or the combination for 24h, serum-starved, and lysates 
subjected to in vitro kinase assay or western blot. V=vehicle=DMSO. Graphs are Mean
±SEM. WM3248, n=2; 435s, n=3. *p<0.05, **p≤0.01 using one-sample t-tests and Holm’s 
adjustment for multiple comparisons.
(c) BRAF or ERK immunoprecipitates from 293T cells transfected with myc-BRAFV600E, 
were incubated with GST-tagged Abl or Arg fragments or with full-length His-tagged, 
kinase-inactive Arg (His-Arg-KR) in a “hot” in vitro kinase assay. Abl-SH2-SH1-KR 
contains an inactive kinase domain (KR). The kinase gel was stained with Coomassie Blue 
to visualize fragment loading (right), and the dried gel was exposed to film (left). Pan ERK 
antibody that recognizes ERK1/2/5 was used for ERK immunoprecipitations.
(d,e) Commercially available, recombinant, full-length GST-BRAF, His-MEK or GST-
ERK2 were incubated in “hot” in vitro kinase assays with recombinant His-Arg-KR (d) or 
with kinase-inactive Abl-KR isolated by immunoprecipitation from 293T cells expressing 
pSRα-Abl-KR (e). Recombinant ERK2 also phosphorylated the “negative” control, GST. 
However, examination of the sequence revealed the presence of a “S/TP” ERK 
phosphorylation site.54
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Figure 4. Abl/Arg drive BRAFV600E-mediated processes, and potentiate BRAFV600E signaling
(a,b) Lysates from vehicle (V; DMSO), nilotinib-treated (24h; a), or siRNA-transfected cells 
(72h; siRNAs=#1; b) were blotted.
(c,d) WM3248 melanoma cells, stably expressing cumate-inducible, Abl-PP/Arg-PP were 
treated with vehicle (DMSO) or BRAF inhibitor, PLX-4720 (1μM), in the absence (c) or 
presence (d) of cumate (0.5X; 24h), and lysates blotted.
(e,f) Tritiated thymidine incorporation (e) or matrigel boyden chamber invasion (f) was 
assessed using WM3248 cells transfected with vector or Abl-PP+Arg-PP, expressing 
scrambled or BRAF siRNA (#1). Matrigel invasion was assessed using IGF-1 (10nM) as 
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chemoattractant at a 48h timepoint. Vec=vector, PP=Abl/Arg-PP, Scr=scrambled siRNA, 
BR=BRAF siRNA. (e) Mean±SEM, n=3. *p<0.05 using one-sample (vs. vector) or two-
sample t-tests. (f) Mean±SEM, n=2, *p=0.05, using a one-way ANOVA followed by 
Tukey’s HSD test. The homogeneity of variance assumption was assessed by Bartlett’s test 
prior to using ANOVA. Aliquots of cells were lysed and blotted (below).
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Figure 5. Abl/Arg and Akt pathways synergize to promote melanoma survival, cell cycle 
progression, and colony formation
(a) Cell Viability (CellTiter Glo) was assessed in treated cells (72h). Representative 
experiments of n=3.
(b) Combination Indices (CI) from n=3 from experiments in (a) were obtained using 
CalcuSyn software. Mean±SEM. CI values >1 =antagonism; =1-additivity, <1=synergy.
(c,d) Drug-treated cells (72h) were washed and colonies allowed to form for 14d (c) or 7d 
(d). For (d), cells were treated for 72h, 8d after plating. Drug concentrations are in 
parentheses (μM).
Jain et al. Page 20
Oncogene. Author manuscript; available in PMC 2017 October 03.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
(e) Colony forming assay using WM3248 cells stably expressing a non-targeting shRNA 
(Scr) or an shRNA that targets Abl and Arg, treated with vehicle or MK-2206 for 5 days. 
The graph indicates the percent inhibition by MK-2206 as compared to vehicle (DMSO). 
Mean±SEM, n=3. *p=0.05, using a two sample t-test.
(f) BrdU/FACS cell cycle analysis on treated cells (72h).
(g) Western blots on lysates from treated cells (72h).
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Figure 6. Inhibitors targeting Abl/Arg and Akt pathways cooperate to prevent melanoma 
growth, in vivo.
(a,b) Cell lines were orthotopically injected into athymic nude mice, and mice treated with 
vehicles, nilotinib (33mg/kg), MK-2206 (90mg/kg-WM3248; 120mg/kg-UACC-903) or the 
combination, 11 (a) or 12 (b) days following establishment of tumors (graphed as Day 0; 
tumors were 30–100mm3). Tumor volume=(LxW2/2), Mean±SEM. ***p<0.001, *p<0.05, 
using a linear mixed model with fixed effects of treatment time and their interactions, and 
random effects of intercept and slope. WM3248: vehicle, n=5; nilotinib, n=8; MK-2206, 
n=8; nilotinib+MK, n=7. UACC: all groups, n=10.
(c) Final ending body weight for mice in (a,b).
(d) Immunohistochemical staining with pRB (S807/811) antibody on representative 
UACC-903 tumors (b).
(e) Xenograft assay using WM3248 cells stably expressing non-targeting shRNA (Scr) or 
Abl/Arg shRNA, treated with vehicle or MK-2206 (120mg/kg) 9 days after injection (Day 
0). Tumor volumes were averaged for treatment days 11,13,15,17, and percent inhibition for 
control versus Abl-Arg shRNA groups graphed. Mean±SEM ***p<0.0001 using two sample 
t-test. Vector/vehicle, n=6; vector/MK, n=7; Abl/Arg-shRNA/vehicle, n=7; Abl/Arg-
shRNA/MK, n=6.
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Figure 7. Model for Abl/Arg activation and signaling in melanoma
BRAFV600E contributes to Abl and Arg activation by recruiting Abl/Arg to the signaling 
complex where ERK (and also potentially BRAF) phosphorylate Abl/Arg. This prevents 
nuclear targeting of Abl and promotes phosphorylation of Abl and Arg by SFKs. Once 
activated, Abl/Arg are required for BRAFV600E induction of the EMT transcription factor 
switch, invasion, and proliferation, and potentiate BRAFV600E signaling, potentially by 
increasing BRAF expression. Finally, Abl/Arg cooperate with a parallel, compensatory 
signaling pathway (PTEN loss/Akt activation) to promote melanoma growth and survival.
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